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Abstract
Introduction: This study evaluated prevalence and predictors of osteoporosis and sarcopaenia in men with HIV.
Material and methods: A total of 220 men with HIV were screened, of which 115 men, 30–50 years-age, having at least one-year follow-
up, underwent hormonal and DEXA analysis. Forty controls were also evaluated.
Results: Males with HIV had significantly lower BMD and Z-scores at all sites. Osteoporosis was diagnosed in 64.35%, the common-
est site being radius total (49.56%), followed by radius 33% (45.21%), radius ultra distal (36.52%), lumbar spine (19.13%), neck of femur 
(17.39%), and total femur and greater trochanter (7.82% each). HIV patients had significantly lower fat mass (FM), lean mass (LM), total 
fat percentage, bone mineral content, gynoid fat, and percentage skeletal muscle mass (PSMM). Men with osteoporosis had higher use of 
anti-retroviral therapy (ART), immune reconstitution inflammatory syndrome (IRIS), tuberculosis, and lower FM, LM, and PSMM. Logistic 
regression revealed that PSMM, age, and delta (Δ) CD4 count (change in CD4 count after 6–12 months of ART, compared to pre-ART) 
were the best predictors of osteoporosis. Greater PSMM was associated with decreased osteoporosis, without adjusting for any variable 
(Model-1), adjusting for disease duration, tuberculosis and IRIS (Model-2), and model-2 plus gonadotropins and sex steroids (Model-3). 
Greater ΔCD4 count and age were associated with increased osteoporosis after adjusting for different models. Sarcopaenia was observed 
in 40% of men and in none of the controls.
Conclusions: Men with decreased skeletal mass, age, severe immune dysfunction at diagnosis, having rapid increase in CD4 count fol-
lowing ART and IRIS have higher risk of osteoporosis in the long run. (Endokrynol Pol 2017; 68 (6): 642–651)
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Streszczenie
Wstęp: Badanie przeprowadzono w celu oceny częstości występowania oraz czynników predykcyjnych osteoporozy i sarkopenii 
u mężczyzn zakażonych HIV.
Materiał i metody: Przebadano 220 mężczyzn zakażonych HIV, spośród których u 115 (w wieku 30–50 lat obserwowanych przez rok) 
wykonano badania hormonalne i dwuenergetyczną absorpcjometrię rentgenowską (dual-energy X-ray absorptiometry, DEXA). Ocenie 
poddano również 40 osób tworzących grupę kontrolną.
Wyniki: Mężczyźni zakażeni HIV mają istotnie mniejszą gęstość mineralną kości (bone mineral density, BMD) i wartości Z-score w całym 
szkielecie. Osteoporozę rozpoznano u 64,35% chorych, a najczęstsze lokalizacje obejmowały całą kość promieniową (49,56%), 33% kości 
promieniowej (45,21%), dystalny odcinek kości promieniowej (36,52%), kręgosłup lędźwiowy (19,13%), szyjkę kości udowej (17,39%), 
całą kość udową i krętarz większy (7,82% każde). U pacjentów zakażonych HIV stwierdzono istotnie niższe wartości masy tkanki 
tłuszczowej (fat mass, FM), masy beztłuszczową (lean mass, LM), całkowitego odsetka tkanki tłuszczowej, zawartości minerałów w kości, 
tkankę tłuszczową gynoidalną, procentowej masę mięśniowo-szkieletową (percent skeletal muscle mass, PSMM). U mężczyzn z osteoporozą 
częściej stosowano leczenie przeciwretrowirusowe (anti-retroviral therapy, ART), a także częściej stwierdzano u nich zespół rekonstytucji 
immunologicznej (immune reconstitution inflammatory syndrome, IRIS), gruźlicę oraz niższe wartości FM, LM i PSMM. Metodą regresji logi-
stycznej wykazano, że najsilniejszymi czynnikami predykcyjnymi osteoporozy były PSMM, wiek i przyrost liczby (Δ) CD4 (zmiana liczby 
CD4 po 6–12 miesiącach ART w porównaniu z wartościami sprzed ART). Wyższa PSMM wiązała się z mniejszą częstością osteoporozy 
w następujących modelach: bez korygowania względem jakichkolwiek zmiennych (model-1), po skorygowaniu względem czasu trwania 
choroby, obecności gruźlicy i IRIS (model-2) oraz model-2 plus gonadotropiny i steroid płciowe (model-3). Większy przyrost liczby limfo-
cytów CD4 i starszy wiek wiązały się dodatnio z występowaniem osteoporozy po skorygowaniu względem różnych modeli. Sarkopenię 
obserwowano u 40% chorych z HIV, natomiast nie stwierdzono jej u żadnej osoby z grupy kontrolnej.
Deep Dutta, Department of Endocrinology, Diabetology & Metabolic Disorders, Venkateshwar Hospital, Sector-18A Dwarka,  
New Delhi-110075; Phone: +919911544096; e-mail: deepdutta2000@yahoo.com
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Wnioski: Mężczyźni z obniżoną masą szkieletu, w starszym wieku i z ciężkimi niedoborami immunologicznymi w czasie rozpoznania, 
u których następuje gwałtowny wzrost liczby limfocytów CD4 po ART i IRIS, cechują się wyższym ryzykiem osteoporozy w perspektywie 
długoterminowej. (Endokrynol Pol 2017; 68 (6): 643–651)
Słowa kluczowe: osteoporoza, HIV, masa szkieletu, masa beztłuszczowa, masy tkanki tłuszczowej
Introduction
With the increasing burden of the HIV epidemic, 
coupled with better outcomes, endocrinopathies are 
increasingly being encountered in HIV patients [1]. En-
docrinopathies are commonly associated with impaired 
bone health [2, 3]. In a meta-analysis, patients with HIV 
had three-times higher prevalence of low bone mineral 
density (BMD), compared to controls [4]. Globally, high 
prevalence of vitamin-D deficiency has been observed 
in patients with HIV [5, 6]. Most of the global data on 
BMD in HIV is available from males, predominantly 
Caucasians [7]. Most of these studies are limited by 
a lack of evaluation of representative controls [7].
Alterations in body composition are known to have 
an impact on bone health in non-HIV infected individu-
als [8]. A variety of patterns of alterations in lean mass 
(LM), fat mass (FM), and bone mineral content (BMC) 
have been reported in HIV [9]. However, bone health 
and body composition alterations among Indians with 
HIV has not been evaluated. Hence this study aimed 
to assess the burden of low BMD (osteoporosis) and 
determine its predictors in asymptomatic young men 
with HIV infection. 
Material and methods
The anti-retroviral therapy (ART) clinic at our centre 
is an apex referral centre, functional since April 2004, 
established by the National AIDS Control Organisation 
(NACO) of India and the World Health Organisation 
(WHO) [1]. Consecutive ambulatory males, 30–50 years 
of age, with serologically documented HIV infection, 
in stable clinical condition, without any acute, severe 
illness, attending the ART clinic, were considered. 
Men above 30 years of age were only considered for 
this study because peak bone mass is usually reached 
by 29 years of age [2]. Also, patients above 50 years of 
age were excluded to eliminate patients with senile/ 
/age-related bone loss. Severely ill patients with mul-
tiple co-morbid states, which would warrant hospital 
admission, patients with known endocrinopathies 
(hypogonadism, hypopituitarism, hypothyroidism, 
hypocortisolism) were excluded. Patients with a history 
of hospital admissions in the preceding two months 
were also excluded. Patient records were reviewed, and 
those having clinical data of at least one-year follow-
up were further evaluated. Patients with available 
CD4 cell counts at diagnosis (pre-HAART) and at first 
follow-up (6–12 months after diagnosis) were included. 
The study protocol was explained, and only those who 
gave informed, written consent were included. The 
institutional Ethics Committee approved the study 
protocol. The period of study was from August 2015 
until December 2016.
Data were collected regarding duration of HIV infec-
tion and details of highly active anti-retroviral therapy 
(HAART). Data was also collected regarding past or 
current evidence of opportunistic infections (bacterial, 
viral, and fungal). Patients underwent detailed clinical 
assessment, including anthropometry. Patients were 
called on subsequent days in fasting state for blood 
sampling. Blood samples of 5 ml each were collected 
in plain and EDTA vacutainers (Becton Dickinson). 
Serum was separated from the blood collected in plain 
vacutainers and processed immediately for routine 
biochemical analysis, and one aliquot of serum was 
stored at –20°C for specific immunological (hormonal) 
assays. The EDTA sample was processed for haemato-
logical analysis.
Chemiluminescent microparticle immunoassay 
(VITROS® ECiQ Immunodiagnostic System, Johnson & 
Johnson, USA) was used for estimation of 25-hydroxy-
vitamin-D (25OHD), prolactin, testosterone, luteinising 
hormone (LH), and follicle stimulating hormone (FSH). 
Serum 25OHD assay had an analytical sensitivity of 
19.97 nmol/L, analytical range of 19.97–374.40 nmol/L, 
and intra and inter-assay coefficient of variation (CV) 
of 3.4% and 5.5%, respectively. Testosterone assay had 
analytical sensitivity of 0.16 mcg/dl, analytical range 
of 0.17–75.06 nmol/L, and intra and inter-assay CV of 
3.8% and 7.4%, respectively. LH assay had analytical 
sensitivity of 0.216 IU/L, analytical range of 0.216–200 
IU/L, and intra and inter-assay CV of 8.8% and 11.3%, 
respectively. FSH assay had analytical sensitivity of 
0.66 IU/L, analytical range of 0.66-200 IU/L, and intra 
and inter-assay CV of 2.8% and 10.1%, respectively. 
Serum calcium, phosphate, alkaline phosphate, and 
renal function tests were done using clinical chemis-
try auto-analyser based on dry chemistry micro-slide 
technology (VITROS® 350 chemistry system, Johnson 
& Johnson, USA). CD4 cell count was performed using 
flow cytometry (Becton Dickinson Immunocytochem-
istry Systems, San Jose, CA).
All patients underwent BMD assessment by dual-
energy X-ray absorptiometry (DEXA; Discovery Wi 
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Series, Serial Number: 84571; Hologic Inc., Waltham, 
MA) at lumbar spine (LS, L1–L4 anteroposterior), left 
proximal femur [neck (NOF), greater trochanter (GT) 
and total femur (TF)], and left forearm regions [ra-
dius 33%, ultra-distal (UD) and radius total]. Quality 
control procedures were done as per manufacturer ’s 
recommendations. A trained technician in the de-
partment performed all scans. The instrument was 
calibrated on a daily basis, using phantom provided 
by the manufacturer, and the CV at different sites 
was found to be < 1.0% over the duration of the 
study. The manufacturer ’s appointed service engi-
neer reviewed the calibration data and performed 
a scanner maintenance check to ensure the system’s 
performance before, at the beginning, and at the end 
of the study to confirm that no instrumentation drift 
occurred during the study period. The BMD of the 
subjects was recorded in terms of absolute mineral 
content (in g/cm2) at various sites. Due to significant 
differences in the ages of patients in the study (30–50 
years), Z-score [number of standard deviations (SD) 
away from average value of age and gender specific 
reference group] was used to compare BMD across 
the groups. Osteoporosis at any site was diagnosed 
if Z-score was < –2 SD [10]. T-score was not used for 
defining osteoporosis because it has been established 
for diagnosis of osteoporosis in the female post-
menopausal state [8]. 
DEXA was also used for estimation of whole-body 
bone mineral content (BMC) (kg), total body fat (kg), 
percentage fat mass (%), fat mass (FM) (kg), lean mass 
(LM) (kg), android fat (kg), and gynoid fat (kg). Body 
composition analyses of soft tissues were performed 
using QDR2000 product software, version 7.10A (Ho-
logic). The lower border of the android region was 
set at upper border of pelvis. The upper border of 
the android region was set at a level being 20% of the 
distance from the upper border of the pelvis to the 
neck. The upper border of the gynoid region was set 
at the level below the upper border of the pelvis at 
a distance of 1.5 times the length of the android re-
gion. The lower border of the gynoid region was set 
at the level at which the length of the gynoid region 
was twice the length of the android region [1, 11]. The 
reproducibility of DEXA measurements was derived 
from the root mean square standard deviation of two 
repeat measurements [1, 11]. The technique precision 
for body composition variables was 12.32 g for BMC 
(0.96% CV), 166.3 g for LM (0.74% CV), and 156.2 g 
for FM (0.72% CV). Clinical, biochemical, and DEXA 
parameters were also collected from 40 age-, sex-, and 
BMI-matched healthy controls, recruited from the 
nursing staff of the institute, who had given informed 
written consent.
Sarcopaenia has been defined as progressive and 
generalised loss of skeletal muscle mass and strength, 
associated with increased morbidity and mortality [12]. 
Documenting low muscle mass is an important com-
ponent of assessing sarcopaenia. The percentage of 
skeletal muscle mass (PSMM) (total lean mass/weight 
x 100) was calculated in patients and controls [12]. 
Low skeletal mass volume (PSMM) has been used to 
define sarcopaenia [12]. Due to lack of normative date 
from the India population, according to the European 
Working Group on Sarcopaenia in Older People recom-
mendations, a PSMM of < 2 SD below the mean in the 
healthy control group was used to define sarcopaenia 
[13]. Studies have shown that PSMM provides a better 
and higher estimation of sarcopaenia when DEXA is 
used as a tool for assessment [12, 13].
Immune reconstitution inflammatory syndrome 
(IRIS) in HIV-infected patients is characterised by 
clinical deterioration secondary to re-establishment 
of immunity following HAART [14]. It is usually ob-
served in patients with low baseline CD4 count, which 
increases rapidly following HAART initiation. HAART 
has been linked to increased systemic inflammation 
and autoimmunity [14, 15]. IRIS has been defined as 
CD4 count > 200 cells/mm3 in patients who previously 
had CD4 counts < 100–200 cells/mm3 [16]. Hence 
patients in our study with baseline CD4 counts < 
200 cells/mm3, which increased to > 200 cells/mm3 
at first follow-up following HAART initiation, were 
defined as having IRIS.
Results
A total of 220 consecutive males with HIV were 
screened, of which 115 who fulfilled all criteria and 
gave consent underwent hormonal and DEXA analy-
sis (Figure 1). In addition, 40 healthy age-, sex-, and 
BMI-matched controls underwent the same set of 
investigations. The median age of our patients with 
HIV infection was 40 years, having median disease 
duration of 38 months, with 90.43% on HAART, 35.65% 
having history of tuberculosis, 51.3% having history of 
IRIS, and 93.05% patients having vitamin-D deficiency/ 
/insufficiency (Table I). Males with HIV had significantly 
lower BMD and corresponding Z-scores at all the sites 
evaluated (LS, TF, NOF, greater trochanter, radius total, 
radius UD, and radius 33%), as compared to controls 
(Table II). Osteoporosis involving at least any one site 
was observed in 74 (64.35%) males with HIV as com-
pared to six (15.00%) individuals in the control group 
(P < 0.001). The most common site of osteoporosis 
among HIV-infected males was radius total (49.56%; 
n = 57), followed by radius 33% (45.21%; n = 52), radius 
UD (36.52%; n = 42), LS (19.13%; n = 22), NOF (17.39%; 
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Figure 1. Flowchart elaborating the study protocol and flow of patients
Rycina 1. Schemat przedstawiający przebieg badania wśród pacjentów
n = 20), total femur, and greater trochanter (7.82%; 
n = 9 each) (Table II). Patients with HIV had significantly 
lower total fat mass (P < 0.001), LM (P = 0.024), total 
fat percentage (P < 0.001), BMC (P = 0.039), gynoid 
fat (P < 0.001), and PSMM (P = 0.05), as compared to 
controls (Table II). 
Among males with HIV, those with osteoporosis 
had higher use of HAART (P = 0.007), higher his-
tory of IRIS (P = 0.049) and tuberculosis (P = 0.056; 
approached statistical significance), and lower FM 
(P = 0.006), LM (P = 0.012), and PSMM (P = 0.004) (Table III). 
Binary logistic regression analysis revealed that PSMM, 
age, and delta (Δ) CD4 count (change in CD4 count at 
6–12-month follow-up with regard to CD4 cell count 
at diagnosis) were consistently the best predictors 
of occurrence of osteoporosis. A greater PSMM was 
associated with decreased osteoporosis risk, without 
adjusting for any variable (Model 1), after adjusting 
for disease duration, history of tuberculosis, and IRIS 
(Model 2), and after adjusting for variables in Model 2 
plus LH, FSH, oestradiol, and testosterone (Model 3) 
(Table IV). A greater increment in CD4 count (Δ CD4 
count) was associated with increased risk of osteoporo-
sis after adjusting for Model 1 and Model 3. Increased 
age was associated with increased risk of osteoporosis 
after adjusting for variables in Model 2 and 3 (Table IV).
PSMM in controls and males with HIV was 67.08 
± 4.11% and 63.74 ± 10.66%, respectively (P = 0.05). 
PSMM < 58.86% (2 SD lower than the mean in controls) 
was defined as sarcopaenia (vide supra) [11]. Using this 
definition, sarcopaenia was observed in 46 males (40%) 
with HIV infection but in none of the control individuals. 
35 out of 74 HIV males with osteoporosis (47.29%) had 
sarcopaenia, in contrast to 11 out of 41 males without os-
teoporosis (26.83%) (P = 0.029). 64.35% of patients in the 
HIV group (n = 115) had osteoporosis, in contrast to 15% 
in the control group (n = 40). This evaluation achieved 
> 99.9% power, keeping type-I error (alpha) at 5%.
Discussion
Bone mineral (BM) loss in HIV is multifactorial. Im-
mune dysregulation and systemic inflammation 
(increased circulating levels of cytokines viz. tumour 
necrosis factor alpha and interleukins, among others) 
play a role in increased receptor activator of nuclear 
factor kappa B (RANK) ligand secretion from os-
teoblasts, along with increased RANK expression on 
osteoclasts, leading to osteoclast activation and sup-
pression of osteoblasts [17]. HIV viral proteins (vpr 
and gp120) promote osteoclast activity, and p55-gag 
suppresses osteoblast activity, in-vitro [18]. Malnutri-
tion, underweight, physical inactivity, malabsorption, 
hypogonadism, glucocorticoids, vitamin-D deficiency, 
substance abuse, and smoking all contribute to BM loss 
in HIV [17]. The HIV-infected patients in our study had 
a high prevalence of vitamin-D deficiency/insufficiency, 
reflective of high vitamin-D deficiency state in the 
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general population [19, 20]. Vitamin-D deficiency, as 
well as its classical role in calcium absorption and bone 
formation, has been linked with increased systemic 
inflammation, immune dysfunction, autoimmunity, 
and secondary hyperparathyroidism, which may fur-
ther accentuate bone loss [21, 22].
In an abstract presented at the 2014 annual confer-
ence of the International AIDS Society (the only previ-
ous report from India), Dravid et al. reported 29.6% 
and 36.6%, respectively, HAART naïve (n = 40) and on 
HAART patients (n = 496) to have osteoporosis [23]. 
However, details from that study are not available. In 
contrast, the burden of osteoporosis (at any one site) 
among young men with HIV is much higher (64.35% 
patients) in our study, predominantly involving the 
wrists (36–49%), and much lower at the spine and hip 
(7–19%). The high prevalence of vitamin-D may con-
tribute to the increased bone loss at wrists observed in 
our study (due to associated secondary hyperparathy-
roidism, which is well known to predominantly effect 
the peripheral/wrist BMD) [2]. However, serum intact 
parathyroid hormone levels were not evaluated in this 
study, which is a limitation.
Our study demonstrated that decreased skeletal 
mass (PSMM) was the strongest and best predictor of 
osteoporosis in males with HIV. Skeletal mass is the pre-
dominant component of lean mass in the body, which 
results in more mechanical loading of the body, thus 
having a positive impact on bone mass [24, 25]. Skeletal 
muscles in addition cause dynamic loading of the mus-
cles. Bone adapts more to dynamic muscle load than to 
static load, explaining the stronger effect of skeletal mass 
(lean mass) over BMD, as compared to fat mass [26]. This 
also explains the beneficial effect of physical activity on 
bone health, which is associated with better skeletal 
mass, and decreased falls, thus deceasing fracture risk 
[25, 26]. Sarcopaenia is a measure of decreased muscular 
volume and function. Sarcopaenia was observed in 40% 
of males with HIV infection but in none of the controls 
individuals, which further highlights the link between 
muscle mass and bone mineral loss. Poor nutrition, in-
creased systemic inflammation, hormonal alterations, 
and neuromuscular and mitochondrial dysfunction 
(myopathy, polyneuropathy, wasting syndrome) are 
some of the factors responsible for sarcopenia in HIV 
[27–32]. A study in males with HIV infection from Cleve-
land, USA also documented a high prevalence of low 
BMD (68.2%) and sarcopaenia (21.9%) [33]. In that study, 
loss of LM was seen, with an accompanying increase in 
central fat accumulation and peripheral fat atrophy in 
HIV patients, as compared to controls [33]. The term, 
“sarco-osteoporosis” is increasingly being used to high-
light the impact of the neuromuscular system on bone 
health and osteoporotic fractures [34, 35].
After PSMM, ΔCD4 cell count (change in CD4 cell 
count at 6–12 months after HAART initiation with 
regards to pre-HAART CD4 cell count levels) was 
Table I. Clinical, demographic, and immunological characteristics 
of HIV-infected men in this study
Tabela I. Parametry kliniczne, demograficzne i immunologiczne 
u mężczyzn zakażonych HIV uczestniczących w badaniu
Parameter Patients (n = 115)
Age (years)a 40 [34–44]
Duration of HIV infection (months)a 38 [21–77]
HAART 104 (90.43%)
Nature of HAART NRTI 103 (89.56%)
NNRTI 103 (89.56%)
PI 2 (1.74%)
H/o tuberculosis 41 (35.65%)
H/o opportunistic fungal infection 1 (0.87%)
H/o viral infection* 2 (1.74%) 
IRIS 59 (51.30%)
BMI (kg/m2) 21.61 [19.53–24.93]
CD4 cell count (at diagnosis) (cell/mm3)a 143 [114–230]
CD4 cell count (6–12 month after diagnosis) 
(cell/mm3)a
275 [218–378]
CD4 cell count (at present) (cell/mm3)a 377 [252–494]
Haemoglobin (g/L) 12.99 [11.72–14.15]
Total leucocyte count (cells/mm3)a 6400 [5430–8000]
Erythrocytic sedimentation rate (mm/hr)a 18 [6–26]
Creatinine (mg/dl) 0.7 [0.6–0.9]
Serum glutamic-pyruvic transaminase (IU/L)a 34 [23–58]
Total cholesterol (mmol/L)a 5 [3.99–5.46]
Triglycerides (mmol/L)a 1.75 [1.38–2.26]
Luteinizing hormone (IU/L)(1.4–9.2)a 5.3 [3.5–7.6]
Follicle stimulating hormone (IU/L) (1.6–10.8)a 5.35 [4.01–7.43]
Oestradiol (pmol/L) (72.36–242)a 88.21 [71.91–100.29]
Testosterone (nmol/L) (8.68–34.70)a 11.24 [8.94–15.79]
Prolactin (pmol/L) (< 870)a 452.17 [358–817.39]
Serum 25OHD 
status
< 25 nmol/L 5 (4.35%)
25–50 nmol/L 58 (50.43%)
50–75 nmol/L 44 (38.26%)
≥ 75 nmol/L 8 (6.95%)
All continuous variables expressed as mean (standard deviation); aall 
non-normally distributed variable expressed as median [range]; all discreet 
variables have been expressed as absolute numbers (percentage); anot 
normally distributed; normality checked using Kolmogorov-Smirnov test; 
P < 0.05 considered statistically significant; #P-value calculated using 
Chi-square test;*viral infections include hepatitis-B, hepatitis-C, and others; 
HAART — highly active anti retro-viral therapy; NRTI — nucleoside reverse 
transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitor; 
PI — protease inhibitors; zidovudine (AZT), lamivudine (3TC), stavudine (d4T), 
and/or tenofovir (TDF) were the NRTIs received by the patients; nevirapine 
(NVP) or efavirinez (EFV) were the NNRTIs received by the patients; atazanavir 
(ATV) or ritonavir (RTV) were the PIs received by the patients; IRIS — immune 
reconstitution inflammatory syndrome
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consistently the second-best predictor of osteoporosis 
after adjusting for various variables. A greater ΔCD4 
count was associated with increased osteoporosis. A 
greater ΔCD4 count implies that the patient has a more 
severe immunodeficiency at the disease onset (lower 
pre-HAART CD4 count), explaining the greater increase 
in CD4 count post HAART (better improvement in im-
mune function). Such a CD4 count response is typically 
associated with higher occurrence of IRIS. Indeed, the 
occurrence of IRIS was higher in HIV males with osteo-
porosis as compared to those without osteoporosis in 
our study. A more severe immunodeficiency at disease 
Table II. Clinical, calcium metabolism profile, bone mineral density, and body composition profile of males with HIV infection 
as compared to healthy controls
Tabela II. Parametry kliniczne, metabolizm wapnia, gęstość mineralna kości i skład ciała u mężczyzn zakażonych HIV 
w porównaniu z osobami z grupy kontrolnej
Parameter Males with HIV (n = 115) Healthy controls (n = 40) P-value
Age (years)a 40 [34–44] 39 [32.5–41] 0.147
BMI (kg/m2) 21.78 ± 5.19 22.95 ± 3.14 0.169
Calcium (mmol/L) 2.31 ± 0.14 2.33 ± 0.14 0.601
ALP (µkat/L) 2.07 ± 0.73 2.33 ± 0.80 0.650
25OHD (nmol/L) 47.97 ± 15.95 51.54 ± 11.68 0.195
BMD (L1-L4) (g/cm2)a 0.945 [0.888–1.006] 0.984 [0.954–1.060] < 0.001
Z-Score (L1-L4)a –1.1 [from –1.8 to –0.5] –0.85 [from –1.07 to –0.25] 0.002
Osteoporosis (L1-L4) 22 0 < 0.001
BMD total femur (g/cm2)a 0.938 [0.817–1.041] 1.061 [0.981–1.129] < 0.001
Z-score total femura –0.4 [from –1.1 to 0.2] 0.5 [-0.2–1.00] < 0.001
Osteoporosis total femur 9 0 < 0.001
BMD NOF (g/cm2)a 0.719 [0.635–0.836] 0.831 [0.754–0.983] < 0.001
Z-score NOFa –1.1 [from –1.65 to –0.2] –0.2 [from –0.88 to 0.50] < 0.001
Osteoporosis NOF 20 0 < 0.001
BMD greater trochanter (g/cm2)a 0.661 [0.581–0.725] 0.726 [0.680–0.813] < 0.001
Z-score greater trochantera –0.7 [from –1.33 to –0.2] –0.2 [from –0.48 to 0.30] < 0.001
Osteoporosis greater trochanter 9 0 < 0.001
BMD radius total (g/cm2)a 0.547 [0.497–0.607] 0.588 [0.554–0.631] 0.002
Z-score radius totala –21. [from –2.73 to –0.9] –1.15 [from –2.05 to –0.50] 0.028
Osteoporosis radius total 57 6 < 0.001
BMD radius UD (g/cm2)a 0.394 [0.373–0.461] 0.496 [0.462–0.616] < 0.001
Z-score radius UDa –1.4 [from –2.2 to –0.2] –0.40 [from –0.85 to 1.52] < 0.001
Osteoporosis radius UD 42 0 < 0.001
BMD radius (33%) (g/cm2)a 0.695 [0.642–0.747] 0.677 [0.589–0.743] 0.005
Z-score radius (33%)a –1.9 [from –2.6 to –0.9] –1.1 [from –2.2 to –0.30] 0.200
Osteoporosis radius (33%) 52 5 < 0.001
Total fat mass (kg)a 13.635 [11.813–17.738] 18.119 [15.669–22.686] < 0.001
Total lean mass (kg)a 42.528 [38.660–47.855] 47.532 [43.947–49.843] 0.024
Total bone mineral content (kg)a 2.009 [1.878–2.282] 2.531 [2.088–2.817] 0.039
Total fat percentage (%)a 24.8 [19.6–27.3] 27.6 [24.3–30.8] < 0.001
Android fat (kg)a 1.425 [1.106–2.044] 1.705 [1.202–2.067] 0.969
Gynoid fat (kg)a 1.830 [1.441–2.228] 3.168 [2.903–3.504] 0.005
Android/gynoid ratioa 0.798 [0.542–0.992] 0.509 [0.422–0.634] 0.759
PSMMa 64 [54–73.49] 68.61 [63.37–70.85] 0.050
25OHD — 25-hydroxy-vitamin-D; ALP — alkaline phosphate; BMD — bone mineral density; L1-L4 — lumbar spine L1 to L4; NOF — neck of femur; PSMM — 
percentage skeletal muscle mass; osteoporosis defined as Z-score < –2 standard deviation (SD); normality of variable distribution checked using Kolmogorov-Smirnov 
test; normally distributed variables expressed as mean ± standard deviation; aall non-normally distributed variables expressed as median [25–75th percentile]; P-value 
calculated using unpaired t-test; P < 0.05 considered statistically significant
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Table III. Clinical, biochemical, body composition, and bone mineral density (BMD) profile of HIV-infected males with 
osteoporosis at any site as compared to those having normal BMD at all sites
Tabela III. Parametry kliniczne i biochemiczne, skład ciała i gęstość mineralna kości (bone mineral density, BMD) 
u mężczyzn zakażonych HIV z osteoporozą o jakiejkolwiek lokalizacji w porównaniu z osobami mającymi prawidłową BMD 
we wszystkich lokalizacjach
Parameter HIV males with osteoporosis  
(n = 74)
HIV with normal BMD  
(n = 41)
P-value
Age (years)a 41 [35–47] 35.5 [31–40] 0.006
BMI (kg/m2) 22 ± 4.90 21.76 ± 5.97 0.821
H/o tuberculosis 31 10 0.056
IRIS 43 16 0.049
HAART 71 33 0.007
Duration of diagnosis (months) 39 [19–85] 36 [24–64] 0.289
Calcium (mmol/L) 2.32 ± 0.15 2.32 ± 0.23 0.963
ALP (µkat/L) 1.95 ± 0.59 2.30 ± 0.79 0.071
25OHD (nmol/L) 47.95 ± 14.58 50.02 ± 18.50 0.522
BMD (L1-L4) (g/cm2)a 0.925 [0.795–0.970] 1.004 [0.954–1.073] < 0.001
Z-Score (L1-L4)a –1.3 [from –2.3 to –1.0] –0.4 [from –1.1 to 0.2] < 0.001
BMD total femur (g/cm2)a 0.864 [0.802–0.973] 1.041 [0.953–1.128] < 0.001
Z-score total femura –0.95 [from –1.42 to –0.2] 0.3 [from –0.5 to 0.9] < 0.001
BMD NOF (g/cm2)a 0.655 [0.594–0.784] 0.845 [0.761–0.962] < 0.001
Z-score NOFa –1.2 [from –1.9 to –0.4] 0.15 [from –1.10 to 0.575] < 0.001
BMD greater trochanter (g/cm2)a 0.642 [0.556–0.669] 0.742 [0.715–0.840] < 0.001
Z-score greater trochantera –0.8 [from –1.55 to –0.60] –0.1 [from 0.4 to 0.725] < 0.001
BMD radius total (g/cm2)a 0.532 [0.491–0.560] 0.649 [0.592–0.659] < 0.001
Z-score radius totala –2.6 [from –3.25 to –2.1] –0.25 [from –0.9 to 0.00] < 0.001
BMD radius UD (g/cm2)a 0.381 [0.360–0.407] 0.463 [0.416–0.503] < 0.001
Z-score radius UDa –2.0 [from –2.3 to –1.4] –0.2 [frem –0.8 to 0.00] < 0.001
BMD radius (33%) (g/cm2)a 0.671 [0.625–0.703] 0.752 [0.703–0.816] < 0.001
Z-score radius (33%)a –2.3 [from –2.8 to –1.9] –0.7 [from –1.1 to0.325] < 0.001
Total fat mass (kg)a 13.635 [11.281–15.894] 14.265 [11.866–26.260] 0.006
Total lean mass (kg)a 40.14 [38.03–46.82] 46.296 [40.201–47.855] 0.012
Total bone mineral content (kg)a 1.950 [1.841–2.262] 2.188 [2.102–2.367] 0.001
Total fat percentage (%)a 23.95 [19.3–26.90] 23.9 [19.6–29.65] 0.278
Android fat (kg)a 1.43 [1.10–1.90] 1.49 [1.065–2.464] 0.714
Gynoid fat (kg)a 1.80 [1.44–2.15] 1.961 [1.515–3.111] 0.713
Android/gynoid ratioa 0.75 [0.54–1.00] 0.813 [0.601–0.877] 0.657
PSMMa 60.43 [52–70.97] 66.70 [61.23–77.32] 0.004
CD4 cell count (at diagnosis) (cell/mm3)a 142 [107–201] 162 [122–280] 0.479
CD4 cell count (6–12 month after diagnosis) (cell/mm3)a 317 [220–385] 273 [217–357] 0.121
CD4 cell count (at present) (cell/mm3)a 389 [290–523] 367 [229–447] 0.168
LH (IU/L) (1.4–9.2)a 4.62 [3.26–6.95] 5.63 [3.76–8.87] 0.047
FSH (IU/L) (1.6–10.8)a 5.54 [4.12–7.26] 5.38 [4.07–7.55] 0.184
Oestradiol (pmol/L) (19.71–242)a 92.98 [71.29–99.14] 92.69 [68.39–97.02] 0.697
Testosterone (nmol/L) (8.68–34.70)a 11.40 [8.80–16.30] 10.34 [7.13–13.70] 0.125
Prolactin (pmol/L) (< 870)a 443.5 [339.13–679.56] 495.65 [350.43–665.21] 0.719
25OHD — 25-hydroxy-vitamin-D; ALP — alkaline phosphate; BMD: bone mineral density; IRIS: immune reconstitution inflammatory syndrome; L1-L4 — lumbar spine 
L1 to L4; NOF — neck of femur; PSMM — percentage skeletal muscle mass; normality of variable distribution checked using Kolmogorov-Smirnov test; normally 
distributed variables expressed as mean ± standard deviation; a all non-normally distributed variable expressed as median [25–75th percentile]; P-value calculated using 
unpaired t-test; P < 0.05 considered statistically significant
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onset, greater ΔCD4 count, and IRIS are associated with 
higher systemic inflammation, which may contribute 
to BM loss. Grant PM et al. observed a lower baseline 
CD4 count to be associated with greater BMD loss in 
first two years following HAART [31]. 
In addition, HAART in general is believed to contrib-
ute to osteoporosis [26]. In our study also, patients with 
osteoporosis had higher use of HAART as compared to 
those without osteoporosis. HAART is believed to in-
duce marked BMD loss (2–6%) within the first two years, 
irrespective of antiretroviral agent used [27]. IRIS may 
have a role in this early HAART-related bone loss [28]. 
Protease inhibitors and tenofovir have been most com-
monly linked to BM loss [28]. Tenofovir, through proxi-
mal renal tubular toxicity, causes renal phosphate wast-
ing, explaining BM loss [28, 29]. However, in our study, 
no specific anti-retroviral agent was linked to osteopo-
rosis. Increased age was associated with increased os-
teoporosis after adjusting for variables in Model 2 and 3. 
This can be explained by the physiological age-related 
bone mineral loss in all individuals after the attainment 
of peak bone mass [2, 8].
There are limited data on therapeutic outcomes in 
HIV-associated osteoporosis. Apart from bisphospho-
nates, no other agent has been evaluated in HIV-associ-
ated osteoporosis. Alendronate over a period of 96 weeks 
has been documented to improve BMD in patients on 
HAART [36]. In another randomised controlled trial, two 
annual doses of 4 mg zoledronic acid was demonstrated 
to have a beneficial effect on BMD, which persisted for 
at least five years after the second dose [37].
Limitations of this study include its cross-sectional 
design. Also, visceral and subcutaneous fat could not 
be assessed separately because DEXA and not com-
puted tomography was used for body composition 
analysis. Strengths of this study include the evalua-
tion of a relatively large homogenous cohort of young 
HIV-infected men, with matched healthy controls, 
a cohort that has been less evaluated, and one in which 
bone health assessment would be more meaningful 
because early therapeutic interventions can improve 
long-term outcomes.
To conclude, this study highlights the unrecognized 
significant burden of osteoporosis (64%) and sarcopae-
nia (40%) in young Indian men with HIV infection. 
Evaluation of sarcopaenia has an important role in 
predicting low BMD and osteoporosis in HIV. This 
study highlights the importance of adequate skeletal 
mass, and hence daily exercise and physical activity 
in maintaining bone health. Men with more severe 
immune dysfunction at diagnosis, who were probably 
sicker, with lower CD4 counts at diagnosis, and having 
a more rapid increase in CD4 count following HAART, 
and having history of IRIS have higher risk of osteopo-
rosis in the long run. 
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Table IV. Binary logistic regression analysis showing factors that independently predict the occurrence of osteoporosis at any 
site in males with HIV infection
Tabela IV. Niezależne czynniki predykcyjne występowania osteoporozy w jakiejkolwiek lokalizacji u mężczyzn zakażonych 
HIV na podstawie analizy binarnej regresji logistycznej
Model-1 Model-2 Model-3
Variable Β Exp (B) P-value Β Exp (B) P-value Β Exp (B) P-value
Age 0.057 1.059 0.091 0.072 1.075 0.048 0.086 1.090 0.030
BMI 0.053 1.054 0.407 0.049 1.051 0.463 0.063 1.065 0.355
ΔCD4 Count 0.004 1.004 0.045 0.004 1.004 0.054 0.006 1.006 0.032
Total lean mass –0.00004 0.9999 0.315 –0.0003 0.9999 0.398 –0.00002 0.9999 0.561
Total fat mass –0.00006 0.9999 0.210 –0.0005 0.9999 0.321 –0.00005 0.9999 0.380
PSMM –0.056 0.945 0.031 –0.062 0.940 0.023 –0.066 0.936 0.018
Binary logistic regression was initially performed with all parameters likely to influence the occurrence of osteoporosis [age, body mass index (BMI), duration of HIV 
infection, baseline CD4 count, delta (Δ) CD4 count (change in CD4 count at 6–12-month follow-up with regards to CD4 cell count at diagnosis (baseline)), serum 
25-hydroxy-vitamin-D (25OHD), oestradiol, DHEAS, testosterone, follicle stimulating hormone (FSH), luteinising hormone (LH), total lean mass, total fat mass, android 
(A) fat, Gynoid (G) fat, A/G ratio, percentage skeletal muscle mass (PSMM), history of tuberculosis, opportunistic fungal infections, viral infections (hepatitis-B and 
hepatitis-C), and individual anti retro-viral agents received by the patient]. Parameters with p < 0.2 were included into the final model as elaborated in the table;  
Exp (B): exponentiation of the B coefficient, change in odds ratio with one unit change in predictor variable; for categorical variables, history of tuberculosis and 
nucleoside reverse transcriptase inhibitors (NRTI) use, absence of tuberculosis and absence of NRTI use were taken as reference group; Model 1: without adjustment 
for any variables; Model 2: after adjustment for duration of HIV infection, history of tuberculosis and IRIS; Model 3: after adjustment for variables in Model 2 plus LH, 
FSH, oestradiol, and testosterone levels
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